Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Zometa Picks Up 17% Of Company’s Bisphosphonate Business

Feb 11 2002

• By The Pink Sheet

Related Content

Novartis Zometa Acquisition Cost Of $713 Per Dose Is 2% Higher Than Aredia

Aug 27 2001

Novartis Zometa Data Supports Bone Metastases Use Across Tumor Types

Feb 04 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window